Isomorphic adds MSD to partner roster, and other deals
It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Novartis raises forecasts for three key growth products
Novartis raises sales expectations for three growth products – Kesimpta, Scemblix, and Leqvio – by $4bn as it sets a 5% midterm revenue growth target.
Regeneron's three-monthly gMG drug Livsayis cleared by FDA
Regeneron has joined the crowded gMG market with an siRNA-based therapy, Livsayis, that only needs to be dosed four times a year.
UK modernises gene therapy definition in regulatory revamp
The UK is planning changes to the definition of gene therapies and other genetic medicines, moving to a mechanism-based approach aligned with the EU.
FDA clears Sanofi's Type 3 Gaucher therapy Infilbray
Sanofi's Infilbray has become the first drug to treat neurological symptoms of rare lysosomal storage disorder Type 3 Gaucher disease (GD3) in the US.
Partner Content
CPHI Milan celebrates record attendance figures at this year...
63,000 attendees from 168 countries were welcomed to the Fiera Milano
The PM Awards aren’t just for agencies. They’re for the peop...
For decades, the PM Awards have been a fixture in the pharma and healthcare communications calendar
PMi Awards 2026: innovation, connection and a changing indus...
One of the things I enjoyed most about this year’s PM Society PMi Awards was the sheer breadth of the community in the room.
LEAP HR: Life Sciences Europe
Europe’s Only Industry-Specific Meeting Advancing HR Excellence in Life Sciences
Rational Based Drug Design Summit Europe
Driving Safer, Faster & More Efficient Discovery Across Europe
